Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets
Provided By GlobeNewswire
Last update: May 8, 2025
Pre-NDA Meeting for CTx-1301(dexmethylphenidate) Held April 2, 2025; New Drug Application Submission Targeted for Mid-2025
Non-Dilutive Funding to Accelerate Development of CTx-2103 (buspirone)
Read more at globenewswire.comNASDAQ:CINGW (11/7/2025, 4:00:00 PM)
0.0399
+0 (+13.35%)
3.73
+0.05 (+1.36%)
Find more stocks in the Stock Screener
